Galapagos receives EUREKA innovation label and OSEO funding
Advertisement
Galapagos NV announced that its antibody therapeutics program with MorphoSys and SARM program have been awarded funding by the French governmental organization OSEO. Accordingly, the Paris-based Galapagos R&D center will receive interest free loans from OSEO worth €1.2 M over the next two years. Galapagos will use the loans to help fund the pre-clinical development of SARM candidate drug GLPG0492 for cachexia and the antibody alliance with MorphoSys.
The Galapagos-MorphoSys antibody alliance also has been awarded the innovation label (E! 5036 GALASYS) by EUREKA, a European network that enhances European competitiveness through international collaboration. With the EUREKA label, Galapagos received the no-interest loan from the French governmental organization OSEO to help fund its part of the alliance. The EUREKA label recognizes the partners' combined cutting-edge capabilities to generate novel antibody therapeutics, a rapidly growing market currently worth over €20 billion. Galapagos and MorphoSys are developing fully human antibodies, which are recognized as the next generation of therapeutic antibodies.
"This attractive financing that our Paris-based R&D center has received from OSEO will support two highly innovative programs which we otherwise would have had to finance internally," said Onno van de Stolpe, CEO of Galapagos. "Both of these programs are on-track, with the SARM candidate drug scheduled to enter the clinic early next year."
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
How SARS-CoV-2 takes over the cell's protein factory - “We've discovered three possible approaches to antiviral treatments”
From beer to useful fats and medicines - The spent grain from beer brewing can be used to make microcapsules that can preserve omega-3 oils and medicines
Human antibody against COVID-19 ready for clinical trials - Antibody blocks the cell entry of SARS-CoV-2 and thus prevents the proliferation of corona viruses
New marker for better assessing the severity of Covid-19 - Scientists have found a new marker in the blood of Covid-19 patients. It furnishes insights into the course and development of the disease and could lead to better diagnoses
How the body uses fat to fight infection - “Fighting infection takes a lot of energy and fat stores are huge energy deposits, which provide the fuel for the blood stem cells to power up the immune response”
Cause found for higher sex-specific risk of mortality - A protein causes higher sex-specific risk of severe cancer progression for men
Evotec Announces Three-Year Drug Discovery Collaboration With Novartis
Facio partners with Evotec and initiates FSHD drug discovery programme
Mosquito-repelling chemicals identified in traditional sweetgrass
